Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IO 102 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IO Biotech

    • Most Recent Events

    • 20 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 11 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Apr 2022.
    • 25 Feb 2021 This trial has been completed in Netherlands as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top